COMMUNIQUÉS West-GlobeNewswire

Correction: BioPorto Announces Annual Results for 2023
04/04/2024
Correction: Updated Annual Report attached April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto [...]
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
04/04/2024
GLASGOW, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that [...]
Pharming Group announces the 2024 Annual General Meeting of Shareholders
04/04/2024
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) [...]
BioPorto Announces Annual Results for 2023
04/04/2024
April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
04/04/2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
04/04/2024
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2023 (the “ [...]
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
04/04/2024
New biomarker may facilitate monitoring T1D patients’ health Increase in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG [...]
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
04/04/2024
Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101 study in patients with [...]
Opthea Appoints Sujal Shah to the Board of Directors
03/04/2024
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE [...]
Palisade Bio Announces 1-for-15 Reverse Stock Split
03/04/2024
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for [...]
Attend an Upcoming True Self Awakening Retreat with Body & Brain Yoga Tai Chi
03/04/2024
Body & Brain Yoga Tai Chi is excited to announce an upcoming True Self Awakening Retreat scheduled for April 11-14 in Sedona, Arizona MESA, Ariz., April 03, 2024 (GLOBE NEWSWIRE) -- Body & Brain is excited to [...]
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
03/04/2024
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a [...]
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
03/04/2024
Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) SAN DIEGO, April 03, 2024 [...]
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
03/04/2024
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstract Company plans to provide updated interim data, including safety and [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2024
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the [...]
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/04/2024
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
03/04/2024
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/04/2024
CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/04/2024
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered [...]

Pages